

## References

I-147

1. Imlygic® [package insert]. BioVex, Inc. Cambridge, MA. October 2015. Revised March 2017.
2. Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. *J Clin Oncol*. 2015 Sep 1;33(25):2780-8. doi: 10.1200/JCO.2014.58.3377.
3. FDA News Release: FDA approves first-of-its-kind product for the treatment of melanoma. Available at: [fda.gov](http://fda.gov)
4. [ClinicalTrials.gov](http://ClinicalTrials.gov)
5. Russell S, Peng K, Bell J. Oncolytic virotherapy. *Nature Biotechnology* [serial online]. July 10, 2012;30(7):658-670.
6. National Comprehensive Cancer Network (NCCN). Talimogene laherparepvec. NCCN Drugs & Biologics Compendium. Fort Washington, PA: NCCN; 2017.
7. Talimogene laherparepvec In: DRUGDEX ®Evaluations (Micromedex®). Greenwood Village, CO: Truven Health Analytics; 2017.